Klinikum Friedrichshafen GmbH
- Address
- Roentgenstrasse 2, Fischbach, 88048 Friedrichshafen, Germany
Antithrombotic Strategies in Atrial Fibrillation
The Neurology department at Klinikum Friedrichshafen GmbH is evaluating new blood‑clot prevention approaches for patients with irregular heart rhythm.
- Safety of short‑term P2Y12 inhibitor monotherapy followed by long‑term direct oral anticoagulant
- Comparison with traditional triple therapy
- Impact on major cardiac and cerebral events
These studies aim to simplify treatment while maintaining protection against heart attacks and strokes.
Stroke Prevention after Intracranial Hemorrhage
Researchers are testing whether a low‑dose edoxaban can lower the risk of future stroke in high‑risk atrial fibrillation patients who have survived brain bleeding.
- Evaluation of anticoagulant versus no‑anticoagulant strategies
- Focus on patients with CHA2DS2‑VASc score ≥2
- Monitoring for recurrent intracranial bleeding
The goal is to find a safe balance between preventing clots and avoiding further brain hemorrhage.
Integrated Care for PCI Patients with Atrial Fibrillation
The site is investigating optimal medication regimens for individuals who have undergone percutaneous coronary intervention with stent placement while also managing atrial fibrillation.
- Assessment of bleeding risk with different antithrombotic combinations
- Long‑term outcomes after stent implantation
- Use of modern drug‑eluting stents
Findings will guide clinicians in reducing both cardiac and cerebral complications after heart procedures.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Insel Gruppe AG1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Klinikum Friedrichshafen GmbH
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack | Janssen Cilag International | Phase III | Not Recruiting | Aug 2023 | — |
IMP list
lock Showing 1 of 9 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Acetylsalicylic Acid | 2 | Unknown | 2023-08-04 | 2024-12-16 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.